Reviewed by The Peptide Dispatch Editorial Team · Last reviewed July 6, 2026
Ipamorelin (IPA) is a growth hormone peptide, at the clinical trials stage in the published literature. A selective growth hormone secretagogue that stimulates GH release without significantly affecting cortisol or prolactin levels, making it one of the safest GH-releasing peptides available.
A selective growth hormone secretagogue that stimulates GH release without significantly affecting cortisol or prolactin levels, making it one of the safest GH-releasing peptides available.
| Research Status | Clinical trials |
|---|---|
| Half-Life | 2 hours |
| Administration | Subcutaneous injection |
| Doses Reported in Published Studies | 100-300 mcg |
Selective GHRP receptor agonist, mimics ghrelin to stimulate pituitary GH release without affecting other hormones.
A selective growth hormone secretagogue that stimulates GH release without significantly affecting cortisol or prolactin levels, making it one of the safest GH-releasing peptides available.
Selective GHRP receptor agonist, mimics ghrelin to stimulate pituitary GH release without affecting other hormones.
Ipamorelin is at the following stage in the published literature: Clinical trials. All information is for research and educational purposes only.
Reported half-life: 2 hours.
Reported administration route in the literature: Subcutaneous injection. This is not a recommendation for human use.
Educational content, not medical advice. Effects described are drawn from cited research in study subjects.